ClinicalTrials.gg
CompletedNCT05076045Updated Dec 5, 2024Results posted

Effects of PSAPs on Speech Processing

An interventional study of Personal sound amplification products in Hearing Loss, Age-Related, sponsored by Rotman Research Institute at Baycrest. Completed at 1 site in Canada. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Rotman Research Institute at Baycrest · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
All
01

Study summary

Mild to moderate hearing loss remains undertreated, largely because of the high cost of hearing aids. A promising and much less expensive alternative is the use of personal sound amplification products (PSAPs), which are electronic, portable, over-the-counter devices that amplify sound. Studies have shown that the use of PSAPs provides significant hearing benefits and improves the quality of life for older adults with mild to moderate hearing loss. However, there is insufficient data to determine the impact of PSAPs use on speech processing in the brain.

The purpose of this study is to use electroencephalography (EEG) measurements to assess the neurobiological and behavioral effects of PSAPs on speech perception in noise in individuals with mild to moderate hearing loss.

The investigators expect that the PSAPs use will result in an immediate improvement in the ability to perceive speech-in-noise, supporting that these hearing devices may be a means of restoring communication skills in people with mild to moderate hearing loss. Behavioral benefits will be associated with increased brain activity in auditory regions and connectivity between auditory and speech regions in the brain.

Read the detailed description

This study will consist of two sessions of 3 hours each. On one session, participants will perform the speech-in-noise task without hearing devices and on the other session, participants will perform the speech-in-noise task while wearing personal sound amplification products. The order of the sessions will be counterbalanced across participants. The speech-in-noise task consists in a word discrimination task in babble noise at three signal-to-noise ratios. On each trial, the task is to determine whether two words are identical or different.

02

Conditions studied

  • Hearing Loss, Age-Related

Keywords

  • Hearing loss
  • Speech processing
  • Speech-in-noise
  • Aging
03

In context

Presbycusis

65 studies on the registry are indexed under Presbycusis; 23 are open to participants now.

This study's enrollment of 32 is below the median of 60 across 44 interventional studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

Rotman Research Institute at Baycrest is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right-handed

Exclusion criteria

Exclusion Criteria:

  • Mother tongue not English
  • Language impairment
  • Dementia
  • Cerebrovascular diseases
  • Untreated vision impairment;
  • Tinnitus and otologic disorders
  • Cochlear implant
  • History of prior hearing aid use
  • Diagnosed addiction (alcohol or drugs)
  • Significant medical or neurocognitive conditions or interventions likely to significantly impact cognitive function (e.g., epilepsy, stroke, traumatic brain injury with loss of consciousness > 5 minutes, brain tumor, multiple sclerosis, hepatitis C, developmental delay, electroconvulsive therapy)
  • a diagnosis (based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)) of major depressive disorder with active symptoms within 90 days of study entry, past or present psychosis, or other psychiatric disorders such as obsessive-compulsive disorder, generalized anxiety disorder, and bipolar disorder
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Personal sound amplification products

    Speech perception will be evaluated using personal sound amplification products.

    Device: Personal sound amplification products

  • No intervention
    Control

    Speech perception will be evaluated without using hearing devices.

Interventions

  • DevicePersonal sound amplification products

    Participants will be tested with bilateral personal sound amplification products.

06

What researchers measure

Primary outcomes

  1. Percentage of Correct Responses With and Without PSAPs

    Percentage (%) of correct responses in the speech-in-noise task when using PSAPs and when using no device.

    Time frame: 1 hour

  2. Reaction Time With and Without PSAPs

    Reaction time (in milliseconds) in the speech-in-noise task when using PSAPs and when using no device.

    Time frame: 1 hour

  3. Quick Speech In Noise Score With and Without PSAPs

    Performance on the QuickSIN when using PSAPs and when using no device. The QuickSIN measures the signal-to-noise ratio loss. A high score indicates poorer speech understanding in noise.

    Time frame: 1 hour

  4. Alpha Power (8-12 Hz) During the Processing of the First Word in a Low Noise Condition, With and Without PSAPs

    Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a low noise condition (signal-to-noise ratio of +3 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

    Time frame: 1 hour

  5. Alpha Power (8-12 Hz) During the Processing of the First Word in a Medium Noise Condition, With and Without PSAPs

    Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a medium noise condition (signal-to-noise ratio of 0 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

    Time frame: 1 hour

  6. Alpha Power (8-12 Hz) During the Processing of the First Word in a High Noise Condition, With and Without PSAPs

    Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a high noise condition (signal-to-noise ratio of -3 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

    Time frame: 1 hour

Secondary outcomes

  1. Self-reported Measure of Listening Effort With and Without PSAPs

    Self-reported listening effort in the speech-in-noise task when using PSAPs and when using no device. Participants used a seven-point Likert scale to rate the listening effort required to complete the speech-in-noise task. The specific question was: "Using the scale in front of you, can you estimate how much effort it took you to understand the words in the presence of background noise? If you think that the amount of effort was between two numbers on the scale, it is fine for you to pick a fraction," with number 1 corresponding to "No effort" and number 7 corresponding to "Extreme effort." A high score indicates a greater listening effort.

    Time frame: 1 hour

07

Results

Posted Dec 5, 2024

Participant flow

72 participants were screened for eligibility between March 1, 2022 and September 31, 2022 by telephone interview at Baycrest Hospital in Toronto, Canada.

First Intervention (3 Hours)
Participant flow — First Intervention (3 Hours)
MilestonePersonal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification Products
Started1616
Completed1616
Not completed00
Washout (1 Week)
Participant flow — Washout (1 Week)
MilestonePersonal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification Products
Started1616
Completed1513
Not completed13
Withdrew: Withdrawal by subject13
Second Intervention (3 Hours)
Participant flow — Second Intervention (3 Hours)
MilestonePersonal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification Products
Started1513
Completed1513
Not completed00

Outcome measures

PrimaryPercentage of Correct Responses With and Without PSAPs

Percentage (%) of correct responses in the speech-in-noise task when using PSAPs and when using no device.

Time frame:
1 hour
Reported as:
Mean · percentage of correct answers
Percentage of Correct Responses With and Without PSAPs
percentage of correct answersPersonal Sound Amplification ProductsControl
Percentage of Correct Responses With and Without PSAPs85.2 (83.2 to 87.4)84.0 (81.9 to 86.0)
Statistical analysis
  • Personal Sound Amplification Products vs Control · Mixed Models Analysis · p = 0.03 (This p-value has been adjusted using the Bonferroni correction. The threshold for statistical significance was p = 0.05 (two-sided).)Results of the pairwise comparisons for the SNR by Session interaction in the linear mixed model analysis.
PrimaryReaction Time With and Without PSAPs

Reaction time (in milliseconds) in the speech-in-noise task when using PSAPs and when using no device.

Time frame:
1 hour
Reported as:
Mean · milliseconds
Reaction Time With and Without PSAPs
millisecondsPersonal Sound Amplification ProductsControl
Reaction Time With and Without PSAPs528.7 ± 155.1502.0 ± 145.9
Statistical analysis
  • Personal Sound Amplification Products vs Control · Mixed Models Analysis · p = 0.28 (The threshold for statistical significance was p = 0.05 (two-sided).)
PrimaryQuick Speech In Noise Score With and Without PSAPs

Performance on the QuickSIN when using PSAPs and when using no device. The QuickSIN measures the signal-to-noise ratio loss. A high score indicates poorer speech understanding in noise.

Time frame:
1 hour
Reported as:
Mean · dB
Quick Speech In Noise Score With and Without PSAPs
dBPersonal Sound Amplification ProductsControl
Quick Speech In Noise Score With and Without PSAPs3.6 ± 2.24.6 ± 2.4
Statistical analysis
  • Personal Sound Amplification Products vs Control · Wilcoxon (Mann-Whitney) · p = 0.005 (The threshold for statistical significance was p = 0.05 (two-sided).)
PrimaryAlpha Power (8-12 Hz) During the Processing of the First Word in a Low Noise Condition, With and Without PSAPs

Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a low noise condition (signal-to-noise ratio of +3 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

Time frame:
1 hour
Reported as:
Mean · percentage of power change
Alpha Power (8-12 Hz) During the Processing of the First Word in a Low Noise Condition, With and Without PSAPs
percentage of power changePersonal Sound Amplification ProductsControl
Alpha Power (8-12 Hz) During the Processing of the First Word in a Low Noise Condition, With and Without PSAPs-0.10 ± 0.11-0.12 ± 0.12
Statistical analysis
  • Personal Sound Amplification Products vs Control · Mixed Models Analysis · p = 1.00 (This p-value has been adjusted using the Bonferroni correction. The threshold for statistical significance was p = 0.05 (two-sided).)Result of the pairwise comparisons for the SNR by Session interaction in the linear mixed model analysis.
PrimaryAlpha Power (8-12 Hz) During the Processing of the First Word in a Medium Noise Condition, With and Without PSAPs

Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a medium noise condition (signal-to-noise ratio of 0 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

Time frame:
1 hour
Reported as:
Mean · percentage of power change
Alpha Power (8-12 Hz) During the Processing of the First Word in a Medium Noise Condition, With and Without PSAPs
percentage of power changePersonal Sound Amplification ProductsControl
Alpha Power (8-12 Hz) During the Processing of the First Word in a Medium Noise Condition, With and Without PSAPs-0.09 ± 0.14-0.08 ± 0.15
Statistical analysis
  • Personal Sound Amplification Products vs Control · Mixed Models Analysis · p = 1.00Result of the pairwise comparisons for the SNR by Session interaction in the linear mixed model analysis.
PrimaryAlpha Power (8-12 Hz) During the Processing of the First Word in a High Noise Condition, With and Without PSAPs

Alpha power (8-12 Hz) for a cluster of temporoparietal electrodes (T7, TP7, CP5), measured between 50 and 500 ms after the onset of the first word of the speech-in-noise task, under a high noise condition (signal-to-noise ratio of -3 dB), with and without PSAPs. Alpha power was measured using temporal spectral evolution analysis with EEG. Values are baseline corrected with the pre-stimulus interval period (-500, 0 ms). Higher values indicate greater alpha power compared to the pre-stimulus interval period (i.e., event-related synchronization).

Time frame:
1 hour
Reported as:
Mean · percentage of power change
Alpha Power (8-12 Hz) During the Processing of the First Word in a High Noise Condition, With and Without PSAPs
percentage of power changePersonal Sound Amplification ProductsControl
Alpha Power (8-12 Hz) During the Processing of the First Word in a High Noise Condition, With and Without PSAPs-0.08 ± 0.11-0.01 ± 0.13
Statistical analysis
  • Personal Sound Amplification Products vs Control · Mixed Models Analysis · p = 0.36 (This p-value has been adjusted using the Bonferroni correction. The threshold for statistical significance was p = 0.05 (two-sided).)Result of the pairwise comparisons for the SNR by Session interaction in the linear mixed model analysis.
SecondarySelf-reported Measure of Listening Effort With and Without PSAPs

Self-reported listening effort in the speech-in-noise task when using PSAPs and when using no device. Participants used a seven-point Likert scale to rate the listening effort required to complete the speech-in-noise task. The specific question was: "Using the scale in front of you, can you estimate how much effort it took you to understand the words in the presence of background noise? If you think that the amount of effort was between two numbers on the scale, it is fine for you to pick a fraction," with number 1 corresponding to "No effort" and number 7 corresponding to "Extreme effort." A high score indicates a greater listening effort.

Time frame:
1 hour
Reported as:
Mean · score on a scale
Self-reported Measure of Listening Effort With and Without PSAPs
score on a scalePersonal Sound Amplification ProductsControl
Self-reported Measure of Listening Effort With and Without PSAPs3.8 ± 1.14.2 ± 0.9
Statistical analysis
  • Personal Sound Amplification Products vs Control · Cumulative link mixed model · p = <0.001 (The threshold for statistical significance was p = 0.05 (two-sided).)

Adverse events

Collected over Adverse events were collected during the first and second sessions, over a period of approximately one week.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Personal Sound Amplification Products0/28 (0%)0/28 (0%)0/28 (0%)
Control0/28 (0%)0/28 (0%)0/28 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Personal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification ProductsTotal
Mean74 ± 6.672.23 ± 6.2573.18 ± 6.38
Sex: Female, Male
Sex: Female, Male(Participants)Personal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification ProductsTotal
Female91019
Male639
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Personal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification ProductsTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Personal Sound Amplification Products First, Then ControlControl First, Then Personal Sound Amplification ProductsTotal
Canada151328
08

Study locations

1 site
  • Rotman Research Institute at Baycrest Centre
    Toronto, Ontario M6A 2E1, Canada
09

References and documents

Publications

  • Perron M, Dimitrijevic A, Alain C. Rapid Brain Adaptation to Hearing Amplification: A Randomized Crossover Trial of Personal Sound Amplification Products. Trends Hear. 2025 Jan-Dec;29:23312165251375891. doi: 10.1177/23312165251375891. Epub 2025 Sep 5. PubMed 40910451 ↗
  • Perron M, Lau B, Alain C. Interindividual variability in the benefits of personal sound amplification products on speech perception in noise: A randomized cross-over clinical trial. PLoS One. 2023 Jul 19;18(7):e0288434. doi: 10.1371/journal.pone.0288434. eCollection 2023. PubMed 37467243 ↗

Study documents

  • Protocol and statistical analysis plan · Mar 14, 2022
  • Informed consent form · Apr 11, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Demographic and health information, behavioral results, and EEG recordings will be shared on an open platform only if participants consent. The data will be anonymized using a random generic code. No personally identifiable data will be shared. The code and stimuli of the task will also be shared on the platform.

Supporting information: Study protocol, Analytic code

Time frame: The data will be shared when the article is published and will remain accessible as long as possible.

Access criteria: Data will be shared on an open platform to be determined. The web address of the data sharing will be inserted in the article, and anyone can access the data from this link.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05076045
Lead sponsor
Rotman Research Institute at Baycrest
Responsible party
Claude Alain (Senior Scientist, Rotman Research Institute at Baycrest) — Principal investigator
First posted
Oct 13, 2021
Start date
Mar 1, 2022
Primary completion
Oct 1, 2022
Completion
Oct 1, 2022
Results posted
Dec 5, 2024
Last update
Dec 5, 2024

Study contacts

Claude Alain, PhD
principal investigator · Rotman Research Institute at Baycrest Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion